Treatment
Benefits of using Ferinject®
Ferinject® is shown to improve outcomes for iron deficient HF patients2-6
Ferinject® is supported by a wealth of evidence in treating iron-deficient HF patients2–7
Correcting iron deficiency with Ferinject® could reduce HF hospitalisation rates2,5,7*†
Ferinject® alleviated HF symptoms,2–4 increased exercise capacity2 and improved HRQoL2,6 in HF patients with iron deficiency
Ferinject® offers rapid iron delivery1
- Up to 1000 mg of Ferinject® can be administered in 15 minutes1
Ferinject® offers rapid repletion of iron stores1
References & footnotes
Footnotes
*In the AFFIRM-AHF trial, Ferinject® was associated with a 26% reduction in HF hospitalisations in patients stabilised after an episode of acute HF (RR: 0.74; 95% CI: 0.58, 0.94; P=0.013). AFFIRM-AHF primary endpoint statistical significance was narrowly missed (P=0.059). AFFIRM-AHF was an RCT to compare the effect of Ferinject® vs placebo on HF hospitalisations and CV mortality in iron-deficient patients hospitalised for an episode of acute HF. Iron deficiency defined as ferritin <100 μg/L or 100–299 μg/L with TSAT <20%.5 In an individual patient data meta-analysis of four RCTs (FER-CARS-01, FAIR-HF, EFFICACY-HF and CONFIRM-HF trials) comparing Ferinject® with placebo in 839 patients with systolic HF, Ferinject® was associated with a 59% reduction in recurrent HF hospitalisations (RR: 0.41; 95% CI: 0.23, 0.73; P=0.003).7 In the CONFIRM-HF trial, Ferinject® was associated with a 61% reduction in hospitalisations for worsening HF in stable HF patients (HR: 0.39; 95% CI: 0.19, 0.82; P=0.009). CONFIRM-HF was an RCT to compare the effect of Ferinject® vs placebo on Week 24 change in 6MWT from baseline in 304 patients with chronic HF and iron deficiency.2
†In the CONFIRM-HF trial, Ferinject® was administered as an undiluted intravenous bolus injection over at least 1 minute, which deviated from the approved posology of the SmPC.2 The SmPC should always be consulted for the approved posology and method of administration.
Abbreviations
6MWT, six-minute walk test; CI, confidence interval; CV, cardiovascular; ESC, European Society of Cardiology; Fe, Iron: HF, heart failure; HRQoL, health-related quality of life; ID, iron deficiency; IV, intravenous; RCT, randomised controlled trial; RR, rate ratio; SmPC, Summary of Product Characteristics; TSAT, transferrin saturation.
References
- Ferinject UAE SmPC. Ferinject KSA SmPC.
- Ponikowski P et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36(11):657–68.
- Anker SD et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361(25):2436–48.
- van Veldhuisen DJ et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017;136(15):1374–83.
- Ponikowski P et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 2020;396(10266):1895–904.
- Jankowska EA et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J 2021;42(31):3011–20.
- Anker SD et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail 2018;20(1):125–33.
- McDonagh TA et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44(37):3627–39.
- McDonagh TA et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599–726.
A complete copy of the cited publications may be requested from CSL in your country.
CSL is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
For more information about CSL, visit www.cslvifor.com.
This website is intended for healthcare professionals only.
This is an international campaign for Ferinject®. Please contact your local CSL representative for the latest information specific to your country.